Inventor
HOSSE RALF
CH47 patents
⚠️ This page may combine multiple inventors who share the name “HOSSE RALF”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ROCHE GLYCART AG
21 patentsUS10184009B2Jan 22, 2019
Mutant interleukin-2 polypeptides
ROCHE GLYCART AG37 citations97
US9346872B2May 24, 2016
Interleukin-10 fusion proteins
ROCHE GLYCART AG43 citations96
US11130822B2Sep 28, 2021
Immunoconjugates
ROCHE GLYCART AG16 citations94
US10577429B2Mar 3, 2020
Anti-FAP antibodies and methods of use
ROCHE GLYCART AG17 citations94
US10323098B2Jun 18, 2019
Mutant interleukin-2 polypeptides
ROCHE GLYCART AG25 citations94
US10316104B2Jun 11, 2019
Immunoconjugates
ROCHE GLYCART AG30 citations94
US10253110B2Apr 9, 2019
Anti-FAP antibodies and methods of use
ROCHE GLYCART AG15 citations94
US10202464B2Feb 12, 2019
Immunoconjugates
ROCHE GLYCART AG30 citations94
US9926379B2Mar 27, 2018
Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5
ROCHE GLYCART AG17 citations92
US9206260B2Dec 8, 2015
Anti-CEA antibodies
ROCHE GLYCART AG23 citations92
US11332545B2May 17, 2022
Anti-FAP antibodies and methods of use
ROCHE GLYCART AG6 citations86
US11111312B2Sep 7, 2021
Mutant interleukin-2 polypeptides
ROCHE GLYCART AG8 citations84
US11214622B2Jan 4, 2022
Antibodies specific for DR5 and methods of use
ROCHE GLYCART AG6 citations83
US10155815B2Dec 18, 2018
Bispecific T cell activating antigen binding molecules
ROCHE GLYCART AG12 citations83
US10562949B2Feb 18, 2020
Interleukin-2 fusion proteins and uses thereof
ROCHE GLYCART AG6 citations82
US10040843B2Aug 7, 2018
Interleukin-10 fusion proteins and uses thereof
ROCHE GLYCART AG7 citations82
US9650442B2May 16, 2017
Bispecific anti-EGFR/anti IGF-1R antibodies
ROCHE GLYCART AG14 citations82
US10781258B2Sep 22, 2020
Bispecific T cell activating antigen binding molecules
ROCHE GLYCART AG4 citations72
US12286486B2Apr 29, 2025
Anti-FAP antibodies and methods of use
ROCHE GLYCART AG0 citations62
US10781257B2Sep 22, 2020
Bispecific T cell activating antigen binding molecules
ROCHE GLYCART AG1 citations62
US11365232B2Jun 21, 2022
Interleukin-2 fusion proteins and uses thereof
ROCHE GLYCART AG1 citations60
HOFFMANN LA ROCHE
15 patentsUS10526413B2Jan 7, 2020
Bispecific antibodies specific for OX40
HOFFMANN LA ROCHE23 citations93
US11608376B2Mar 21, 2023
Tumor-targeted agonistic CD28 antigen binding molecules
HOFFMANN LA ROCHE14 citations82
US11780920B2Oct 10, 2023
Antibodies binding to CD3 and CD19
HOFFMANN LA ROCHE4 citations72
US11672858B2Jun 13, 2023
Bispecific antibody molecules binding to CD3 and TYRP-1
HOFFMANN LA ROCHE2 citations72
US11591397B2Feb 28, 2023
Bispecific antibody molecules binding to CD3 and EGFRvIII
HOFFMANN LA ROCHE2 citations72
US10584178B2Mar 10, 2020
Bispecific HER2 antibodies and methods of use
HOFFMANN LA ROCHE2 citations72
US11098099B2Aug 24, 2021
Interleukin-2 fusion proteins and uses thereof
HOFFMANN LA ROCHE5 citations71
US12240911B2Mar 4, 2025
Bispecific antibodies specific for OX40
HOFFMANN LA ROCHE0 citations62
US12215155B2Feb 4, 2025
Antibodies binding to CD3 and CD19
HOFFMANN LA ROCHE1 citations62
US12139553B2Nov 12, 2024
T cell activating bispecific antigen binding molecules
HOFFMANN LA ROCHE0 citations62
US12103982B2Oct 1, 2024
T cell activating bispecific antigen binding molecules
HOFFMANN LA ROCHE0 citations62
US11827711B2Nov 28, 2023
Antibodies binding to NKG2D
HOFFMANN LA ROCHE1 citations62
US12473373B2Nov 18, 2025
Bispecific antibody molecules binding to CD3 and EGFRvIII
HOFFMANN LA ROCHE0 citations61
US11787873B2Oct 17, 2023
Bispecific HER2 antibodies and methods of use
HOFFMANN LA ROCHE0 citations61
US10745470B2Aug 18, 2020
Modified anti-tenascin antibodies and methods of use
HOFFMANN LA ROCHE0 citations52